Go to Jeff Salisbury LWGate Home Page.From: "Katherine Malm" <kmalm@earthlink.net>
Subject: RE: [CANSLIM] APPX -- any idea what is happening
Date: Wed, 28 May 2003 19:11:30 -0500
Next Article (by Author): Re: [CANSLIM] BO, too fast too much "Pritish Shah"
Previous Article (by Author): RE: [CANSLIM] APPX -- any idea what is happening "Katherine Malm"
Top of Thread: [CANSLIM] APPX -- any idea what is happening "Pritish Shah"
Articles sorted by: [Date]
[Author]
[Subject]
This is a multi-part message in MIME format.
- ------=_NextPart_000_003D_01C3254C.F1F95F60
Content-Type: text/plain;
charset="US-ASCII"
Content-Transfer-Encoding: 7bit
Hi Eric, and all...
Your mention of Patrick Soon-Shiong reminded me of a discussion that we had on
the CANSLIM list on APPX back in January. At the time, I was performing due
diligence on the stock and here were my findings:
-----Original Message-----
From: Katherine Malm [mailto:kmalm@earthlink.net]
Sent: Wednesday, January 29, 2003 10:05 AM
Subject: RE:APPX
Oh what a tangled web this turned out to be.
Looking at APPX, the management ownership at 40% caught my eye. I know that
often these numbers are high when the company is owned by a parent company, and
in this case, APPX is owned primarily by American Bioscience from Santa Monica,
CA. (See http://biz.yahoo.com/t/in/a/appx.html for the insider roster.) It's
very difficult to get information on a privately held company, but Chairman
Patrick Soon-Shong has controlling interest, and that with his 500K holdings
directly in APPX gives him 65% controlling interest in APPX. (See
http://www.hoovers.com/co/capsule/6/0,2163,103876,00.html for a note on the 65%
interest).
My Biotech Investors Bible (George Wolff) says that "The FTC is investigating
whether Bristol-Meyers Squibb and a small biotech firm called American
Biosceince conspired to prevent a generic drug company from bringing a
lower-cost version of the anticancer drug Taxol to market. The two companies
under investigation deny allegations by the generic drug maker, IVAX." See a
June '02 NY Times article on the subject at
http://www.vaccinationnews.com/DailyNews/June2002/StatesAccuseBMYFraud.htm.
Follow the path of litigation and see that FSU sued and won over stealing
secrets when American Bioscience hired a researcher away from the University.
http://www.research.fsu.edu/whatsnew/newsletters/documents/newsletter2001_12.pdf
(page 3). Further shenanigans with Hospital supplier Premier add to the yellow
flags http://maillist.linuxmednews.org/pipermail/mednews/2002-March/000139.html.
APPX's official response is at http://www.appdrugs.com/032702PR.htm in which
they state "Despite clarification provided by the company, The Times confused
and mischaracterized a previously reported FTC investigation surrounding a
patent dispute related to generic Taxol between the parent company American
BioScience and certain third party companies, and in which APP played no role.
Furthermore, the article inaccurately reported that there are legal claims
against APP relating to this matter when, in fact, there are none. " In their
SEC filings, they indicate that they have separated themselves from Premier by
repurchasing all the shares held by Premier. "Pursuant to an agreement that
expired March 31, 2001, Premier Purchasing Partners, L.P. (Premier) earned, at
no cost, shares of our common stock based upon the level of our sales to Premier
's partners. During the nine months ended September 30, 2001, the shares earned
by Premier had a fair value of $1,754,000 and were classified as a reduction of
net sales in the accompanying condensed consolidated statements of income. ...On
July 29, 2002, we repurchased all shares of our common stock held by Premier
Purchasing Partners, totaling 2,914,593 shares for $29,758,000 in cash."
(http://www.edgar-online.com/bin/edgardoc/finSys_main.asp?dcn=0001021408-02-0141
37&nad). And yet more litigation "During 1999, VivoRx brought an action against
us, our chairman and chief executive officer and American BioScience relating to
the development of the businesses of American BioScience and us while our
chairman and chief executive officer was also serving as the chief executive
officer and chairman of VivoRx. This action was settled in February 2001 with
American BioScience obtaining clear title and ownership to its intellectual
property, including the intellectual property underlying American BioScience's
ABI-007 product candidate. Under the settlement, we are jointly and severally
liable with American BioScience to pay VivoRx the remaining obligation under the
settlement agreement of $12,000,000 in February 2003, of which American
BioScience has agreed to pay. The respective boards of directors for American
BioScience and us, in consultation with litigation counsel, passed resolutions
allocating $3,400,000 of the total settlement obligation of $34,000,000 to us
and the remaining $30,600,000 to American BioScience. We paid our allocated
portion of the settlement obligation in February 2001. The allocation of the
settlement was primarily based upon American BioScience obtaining clear title
and ownership to its intellectual property, including the intellectual property
underlying American BioScience's ABI-007 product candidate, and, accordingly,
being the primary beneficiary of the settlement. [paragraph} Notwithstanding the
agreed upon allocation of the settlement obligation between American BioScience
and us, we recorded the entire present value of $30,354,000 of the litigation
settlement with VivoRx as an expense for the year ended December 31, 2000. "
The relationship between American BioScience and APPX is complex, wherein APPX
distributed shares to ABI for product licensing agreements on ABI-007.
"Product License Agreement
In November 2001, we entered into a license agreement with American BioScience
under which we acquired the exclusive rights to market and sell ABI-007 in North
America, and which provided for initial license payments of $60,000,000 in
January 2002. This license is perpetual. American BioScience also entered into a
manufacturing agreement with us that grants us exclusive manufacturing rights
for a three-year period. American BioScience is responsible for substantially
all costs associated with the development of ABI-007, except that we agreed to
provide up to $2,000,000 of ABI-007 for use in clinical trials. The cost of the
clinical product was charged to research and development expense in the year
ended December 31, 2001. We are also required to make milestone payments of up
to (a) $60,000,000 for indications related to breast, ovarian and lung cancers
and (b) $32,500,000 for indications relating to prostate cancer and other
indications as agreed upon between American BioScience and us. We also may be
required to make additional milestone payments of up to an aggregate of
$110,000,000 based upon the achievement of particular annual sales levels.
Profits from any sales of ABI-007 will be shared equally with American
BioScience after deducting costs of goods sold, selling expenses and other
appropriate deductions. All costs and expenses related to product recalls and
product liability claims generally will be split equally between American
BioScience and us.
The initial license payment has been accounted for as a distribution of our
stockholders' equity to American BioScience. As of December 31, 2001, the entire
$60,000,000 had been accrued as a distribution payable to American BioScience.
The $60,000,000 was paid to American BioScience in January 2002. The income tax
benefits related to this payment will be credited to the stockholders' equity as
realized. "
But at the same time, APPX holds a note receivable from ABI:
"Payments on behalf of American BioScience's new product development
activities include our administrative salary and benefit allocations, charges
for our employees' services and supplies related to American BioScience's
products in development. Subsequent to September 30, 2002, $1,132,000 has been
repaid by American BioScience.
On December 14, 2001, we received a demand promissory note for the balance
outstanding from American BioScience (Demand Note). The Demand Note bears
interest at a rate equal to the rate of interest on our credit facility (6.0% at
September 30, 2002).
In connection with the execution of the Demand Note, as security for payment
of the obligations under the Demand Note, we entered into a pledge agreement
with American BioScience under which American BioScience pledged and granted us
a security interest in shares of our common stock held by it having a fair
market value equal to 120% of the balance of the Demand Note. "
Balance at September 30, 2002
$
22,724,000
I know that drug development is complex and that it's not all that uncommon
for these suits to float around, but my shenanigans radar is in high gear with
this company as it seems going public was a means of separating themselves to
some degree from liabilities related to the less-than-above-board dealings at
ABI.
-----Original Message-----
From: owner-canslim@lists.xmission.com
[mailto:owner-canslim@lists.xmission.com]On Behalf Of Eric Jaenike
Sent: Wednesday, May 28, 2003 5:03 PM
To: canslim@lists.xmission.com
Subject: Re: [CANSLIM] APPX -- any idea what is happening
From what I can tell, three rumors circulated today: 1. the company pulled out
of a UBS healthcare conference. 2. The SEC is investigating the CEO, Patrick
Soon-Shiong, for violations of Reg FD 3. Some negative research or comments from
Avalon Research regarding the toxicity of APPX's experimental anti-cancer drug
ABI-007. As I understand it, the first 2 are most likely false, the third is
possibly true.
Eric
Roger <gagnonr001@hawaii.rr.com> wrote:
Tomas
Right I am very happy with the $8,000 I was just about to sell when my Gain
when to 25% which it was but I got a overseas phone call. Was on the line
for an hour when I got back to my PC APPX was down $4 I couldn't believe.
When it go to just under$31 I got out..Well now I am looking for another to
buy.. I try to buy 2000 sh for those under 30 and 1,500 or 1,000 for those
above depending. Well I will keep my eyes open for another
Roger
----- Original Message -----
From: "Tomas"
To:
Sent: Wednesday, May 28, 2003 10:54 AM
Subject: Re: [CANSLIM] APPX -- any idea what is happening
> BTW Roger, Congrats on the $8K gain. Half the orginal
> gain... but can't be too greedy :).
>
> tomas
>
> --- Roger wrote:
> > Pritish
> > I don't know what happened but I got out at $31 made
> > about $8,000 profit but
> > was looking at a $16,000 profit earlier in the day
> > well atleast I made
> > something
> > Roger
> > ----- Original Message -----
> > From: "Pritish Shah"
> > To:
> > Sent: Wednesday, May 28, 2003 9:28 AM
> > Subject: [CANSLIM] APPX -- any idea what is
> > happening
> >
> >
> >
> > Does anyone have any idea on what is happening with
> > this stock. It has lost
> > $5 in price in the last hour.
> >
> > Regards,
> > Pritish
> >
> >
> > -
> > -To subscribe/unsubscribe, email
> > "majordomo@xmission.com"
> > -In the email body, write "subscribe canslim" or
> > -"unsubscribe canslim". Do not use quotes in your
> > email.
> >
> >
> >
> > -
> > -To subscribe/unsubscribe, email
> > "majordomo@xmission.com"
> > -In the email body, write "subscribe canslim" or
> > -"unsubscribe canslim". Do not use quotes in your
> email.
>
>
> __________________________________
> Do you Yahoo!?
> Yahoo! Calendar - Free online calendar with sync to Outlook(TM).
> http://calendar.yahoo.com
>
> -
> -To subscribe/unsubscribe, email "majordomo@xmission.com"
> -In the email body, write "subscribe canslim" or
> -"unsubscribe canslim". Do not use quotes in your email.
-
-To subscribe/unsubscribe, email "majordomo@xmission.com"
-In the email body, write "subscribe canslim" or
-"unsubscribe canslim". Do not use quotes in your email.
- ------------------------------------------------------------------------------
Do you Yahoo!?
Free online calendar with sync to Outlook(TM).
- ------=_NextPart_000_003D_01C3254C.F1F95F60
Content-Type: text/html;
charset="US-ASCII"
Content-Transfer-Encoding: quoted-printable
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD>
<META http-equiv=3DContent-Type content=3D"text/html; =
charset=3Dus-ascii">
<META content=3D"MSHTML 6.00.2800.1170" name=3DGENERATOR></HEAD>
<BODY>
<DIV><SPAN class=3D718150700-29052003>Hi Eric, and all...</SPAN></DIV>
<DIV><SPAN class=3D718150700-29052003></SPAN> </DIV>
<DIV><SPAN class=3D718150700-29052003>Your mention of Patrick =
Soon-Shiong reminded=20
me of a discussion that we had on the CANSLIM list on APPX back in =
January. At=20
the time, I was performing due diligence on the stock and here were my=20
findings:</SPAN></DIV>
<DIV><SPAN class=3D718150700-29052003>
<BLOCKQUOTE dir=3Dltr style=3D"MARGIN-RIGHT: 0px">
<DIV class=3DOutlookMessageHeader dir=3Dltr align=3Dleft><FONT =
face=3DTahoma=20
size=3D2>-----Original Message-----<BR><B>From:</B> Katherine Malm=20
[mailto:kmalm@earthlink.net]<BR><B>Sent:</B> Wednesday, January 29, =
2003 10:05=20
AM<BR><B>Subject:</B> RE:APPX<BR><BR></FONT></DIV>
<DIV><SPAN class=3D874021715-29012003>Oh what a tangled web this =
turned out to=20
be.</SPAN></DIV>
<DIV><SPAN class=3D874021715-29012003></SPAN> </DIV>
<DIV><SPAN class=3D874021715-29012003>Looking at APPX, the management =
ownership=20
at 40% caught my eye. I know that often these numbers are high when =
the=20
company is owned by a parent company, and in this case, APPX is owned=20
primarily by American Bioscience from Santa Monica, CA. (See <A=20
=
href=3D"http://biz.yahoo.com/t/in/a/appx.html">http://biz.yahoo.com/t/in/=
a/appx.html</A> for=20
the insider roster.) It's very difficult to get information on a =
privately=20
held company, but Chairman Patrick Soon-Shong has controlling =
interest,=20
and that with his 500K holdings directly in APPX gives him 65% =
controlling=20
interest in APPX. (See <A=20
=
href=3D"http://www.hoovers.com/co/capsule/6/0,2163,103876,00.html">http:/=
/www.hoovers.com/co/capsule/6/0,2163,103876,00.html</A> for=20
a note on the 65% interest).</SPAN></DIV>
<DIV><SPAN class=3D874021715-29012003></SPAN> </DIV>
<DIV><SPAN class=3D874021715-29012003>My Biotech Investors Bible =
(George Wolff)=20
says that "The FTC is investigating whether Bristol-Meyers Squibb and=20
a small biotech firm called American Biosceince conspired to =
prevent a=20
generic drug company from bringing a lower-cost version of the =
anticancer drug=20
Taxol to market. The two companies under investigation deny =
allegations by the=20
generic drug maker, IVAX." See a June '02 NY Times article on the =
subject at=20
<A=20
=
href=3D"http://www.vaccinationnews.com/DailyNews/June2002/StatesAccuseBMY=
Fraud.htm">http://www.vaccinationnews.com/DailyNews/June2002/StatesAccuse=
BMYFraud.htm</A>.=20
Follow the path of litigation and see that FSU sued and won over=20
stealing secrets when American Bioscience hired a researcher =
away=20
from the University. <A=20
=
href=3D"http://www.research.fsu.edu/whatsnew/newsletters/documents/newsle=
tter2001_12.pdf">http://www.research.fsu.edu/whatsnew/newsletters/documen=
ts/newsletter2001_12.pdf</A> (page=20
3). Further shenanigans with Hospital supplier Premier add to the =
yellow flags=20
<A=20
=
href=3D"http://maillist.linuxmednews.org/pipermail/mednews/2002-March/000=
139.html">http://maillist.linuxmednews.org/pipermail/mednews/2002-March/0=
00139.html</A>.=20
APPX's official response is at <A=20
=
href=3D"http://www.appdrugs.com/032702PR.htm">http://www.appdrugs.com/032=
702PR.htm</A> in=20
which they state "Despite clarification provided by the company, The =
Times=20
confused and mischaracterized a previously reported FTC investigation=20
surrounding a patent dispute related to generic Taxol between the =
parent=20
company American BioScience and certain third party companies, and in =
which=20
APP played no role. Furthermore, the article inaccurately reported =
that there=20
are legal claims against APP relating to this matter when, in fact, =
there are=20
none. <SPAN class=3D874021715-29012003>" In their SEC filings, =
they=20
indicate that they have separated themselves from Premier by =
repurchasing all=20
the shares held by Premier. "Pursuant to an agreement that expired =
March 31,=20
2001, Premier Purchasing Partners, L.P. (Premier) earned, at no cost, =
shares=20
of our common stock based upon the level of our sales to =
Premier’s partners.=20
During the nine months ended September 30, 2001, the shares earned by =
Premier=20
had a fair value of $1,754,000 and were classified as a reduction of =
net sales=20
in the accompanying condensed consolidated statements of income. ...On =
July=20
29, 2002, we repurchased all shares of our common stock held by =
Premier=20
Purchasing Partners, totaling 2,914,593 shares for $29,758,000 in =
cash." (<A=20
=
href=3D"http://www.edgar-online.com/bin/edgardoc/finSys_main.asp?dcn=3D00=
01021408-02-014137&nad">http://www.edgar-online.com/bin/edgardoc/finS=
ys_main.asp?dcn=3D0001021408-02-014137&nad</A>).=20
And yet more litigation "During 1999, VivoRx brought an action against =
us, our=20
chairman and chief executive officer and American BioScience relating =
to the=20
development of the businesses of American BioScience and us while our =
chairman=20
and chief executive officer was also serving as the chief executive =
officer=20
and chairman of VivoRx. This action was settled in February 2001 =
with=20
American BioScience obtaining clear title and ownership to its =
intellectual=20
property, including the intellectual property underlying American =
BioScience’s=20
ABI-007 product candidate. Under the settlement, we are jointly and =
severally=20
liable with American BioScience to pay VivoRx the remaining obligation =
under=20
the settlement agreement of $12,000,000 in February 2003, of which =
American=20
BioScience has agreed to pay. The respective boards of directors for =
American=20
BioScience and us, in consultation with litigation counsel, passed =
resolutions=20
allocating $3,400,000 of the total settlement obligation of =
$34,000,000 to us=20
and the remaining $30,600,000 to American BioScience. We paid our =
allocated=20
portion of the settlement obligation in February 2001. The allocation =
of the=20
settlement was primarily based upon American BioScience obtaining =
clear title=20
and ownership to its intellectual property, including the intellectual =
property underlying American BioScience’s ABI-007 product =
candidate, and,=20
accordingly, being the primary beneficiary of the settlement. =
[paragraph}=20
Notwithstanding the agreed upon allocation of the settlement =
obligation=20
between American BioScience and us, we recorded the entire present =
value of=20
$30,354,000 of the litigation settlement with VivoRx as an expense for =
the=20
year ended December 31, 2000. <SPAN=20
class=3D874021715-29012003>"</SPAN></SPAN></SPAN></DIV>
<DIV><SPAN class=3D874021715-29012003><SPAN =
class=3D874021715-29012003><SPAN=20
class=3D874021715-29012003></SPAN></SPAN></SPAN> </DIV>
<DIV><SPAN class=3D874021715-29012003><SPAN =
class=3D874021715-29012003><SPAN=20
class=3D874021715-29012003>The relationship between American =
BioScience and APPX=20
is complex, wherein APPX distributed shares to ABI for product =
licensing=20
agreements on ABI-007. </SPAN></SPAN></SPAN></DIV>
<DIV><SPAN class=3D874021715-29012003><SPAN =
class=3D874021715-29012003><SPAN=20
class=3D874021715-29012003></SPAN></SPAN></SPAN> </DIV>
<DIV><SPAN class=3D874021715-29012003><SPAN =
class=3D874021715-29012003><SPAN=20
class=3D874021715-29012003>"<EM>Product License Agreement </EM></DIV>
<P>In November 2001, we entered into a license agreement with American =
BioScience under which we acquired the exclusive rights to market and =
sell=20
ABI-007 in North America, and which provided for initial license =
payments of=20
$60,000,000 in January 2002. This license is perpetual. American =
BioScience=20
also entered into a manufacturing agreement with us that grants us =
exclusive=20
manufacturing rights for a three-year period. American BioScience is=20
responsible for substantially all costs associated with the =
development of=20
ABI-007, except that we agreed to provide up to $2,000,000 of ABI-007 =
for use=20
in clinical trials. The cost of the clinical product was charged to =
research=20
and development expense in the year ended December 31, 2001. We are =
also=20
required to make milestone payments of up to (a) $60,000,000 for =
indications=20
related to breast, ovarian and lung cancers and (b) $32,500,000 for=20
indications relating to prostate cancer and other indications as =
agreed upon=20
between American BioScience and us. We also may be required to make =
additional=20
milestone payments of up to an aggregate of $110,000,000 based upon =
the=20
achievement of particular annual sales levels. Profits from any sales =
of=20
ABI-007 will be shared equally with American BioScience after =
deducting costs=20
of goods sold, selling expenses and other appropriate deductions. All =
costs=20
and expenses related to product recalls and product liability claims =
generally=20
will be split equally between American BioScience and us. </P>
<P>The initial license payment has been accounted for as a =
distribution of our=20
stockholders’ equity to American BioScience. As of December 31, =
2001, the=20
entire $60,000,000 had been accrued as a distribution payable to =
American=20
BioScience. The $60,000,000 was paid to American BioScience in January =
2002.=20
The income tax benefits related to this payment will be credited to =
the=20
stockholders’ equity as realized. <SPAN=20
class=3D874021715-29012003>"</SPAN></P>
<P><SPAN class=3D874021715-29012003>But at the same time, APPX holds a =
note=20
receivable from ABI:</SPAN></P>
<P><SPAN class=3D874021715-29012003>"Payments on behalf of American =
BioScience’s=20
new product development activities include our administrative salary =
and=20
benefit allocations, charges for our employees’ services and =
supplies related=20
to American BioScience’s products in development. Subsequent to =
September 30,=20
2002, $1,132,000 has been repaid by American BioScience. </P>
<P>On December 14, 2001, we received a demand promissory note for the =
balance=20
outstanding from American BioScience (Demand Note). The Demand Note =
bears=20
interest at a rate equal to the rate of interest on our credit =
facility (6.0%=20
at September 30, 2002). </P>
<P>In connection with the execution of the Demand Note, as security =
for=20
payment of the obligations under the Demand Note, we entered into a =
pledge=20
agreement with American BioScience under which American BioScience =
pledged and=20
granted us a security interest in shares of our common stock held by =
it having=20
a fair market value equal to 120% of the balance of the Demand=20
Note. <SPAN class=3D874021715-29012003>"</SPAN></P>
<P><FONT size=3D2><SPAN class=3D874021715-29012003>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"100%" align=3Dcenter =
border=3D0>
<TBODY>
<TR>
<TD vAlign=3Dbottom width=3D"68%" bgColor=3D#cceeff colSpan=3D2>
<P><FONT face=3D"TIMES NEW ROMAN" size=3D2>Balance at September =
30, 2002=20
</FONT></P></TD>
<TD vAlign=3Dbottom width=3D"2%" bgColor=3D#cceeff>
<P><FONT face=3D"TIMES NEW ROMAN" size=3D2> =
</FONT></P></TD>
<TD vAlign=3Dbottom width=3D"1%" bgColor=3D#cceeff>
<P><FONT face=3D"TIMES NEW ROMAN" size=3D2> =
</FONT></P></TD>
<TD vAlign=3Dbottom width=3D"12%" bgColor=3D#cceeff>
<P align=3Dright></P></TD>
<TD vAlign=3Dbottom width=3D"2%" bgColor=3D#cceeff>
<P><FONT face=3D"TIMES NEW ROMAN" size=3D2> =
</FONT></P></TD>
<TD vAlign=3Dbottom width=3D"1%" bgColor=3D#cceeff>
<P><FONT face=3D"TIMES NEW ROMAN" size=3D2>$ </FONT></P></TD>
<TD vAlign=3Dbottom width=3D"12%" bgColor=3D#cceeff>
<P align=3Dright><FONT face=3D"TIMES NEW ROMAN" =
size=3D2>22,724,000=20
</FONT></P></TD>
<TD vAlign=3Dbottom width=3D"1%" bgColor=3D#cceeff>
<P><FONT face=3D"TIMES NEW ROMAN" size=3D2> =20
</FONT></P></TD></TR></TBODY></TABLE></SPAN></FONT></P></SPAN></SPAN>
<P><SPAN class=3D874021715-29012003>I know that drug development is =
complex and=20
that it's not all that uncommon for these suits to float around, but =
my=20
shenanigans radar is in high gear with this company as it seems going =
public=20
was a means of separating themselves to some degree from liabilities =
related=20
to the less-than-above-board dealings at ABI.</SPAN></P>
<P><SPAN=20
class=3D874021715-29012003></SPAN></SPAN></SPAN> </P></BLOCKQUOTE></=
SPAN></DIV>
<BLOCKQUOTE>
<DIV class=3DOutlookMessageHeader dir=3Dltr align=3Dleft><FONT =
face=3DTahoma=20
size=3D2>-----Original Message-----<BR><B>From:</B>=20
owner-canslim@lists.xmission.com=20
[mailto:owner-canslim@lists.xmission.com]<B>On Behalf Of </B>Eric=20
Jaenike<BR><B>Sent:</B> Wednesday, May 28, 2003 5:03 PM<BR><B>To:</B>=20
canslim@lists.xmission.com<BR><B>Subject:</B> Re: [CANSLIM] APPX -- =
any idea=20
what is happening<BR><BR></FONT></DIV>
<DIV>From what I can tell, three rumors circulated today: 1. the =
company=20
pulled out of a UBS healthcare conference. 2. The SEC is investigating =
the=20
CEO, Patrick Soon-Shiong, for violations of Reg FD 3. Some negative =
research=20
or comments from Avalon Research regarding the toxicity of APPX's =
experimental=20
anti-cancer drug ABI-007. As I understand it, the first 2 are most =
likely=20
false, the third is possibly true.</DIV>
<DIV> </DIV>
<DIV>Eric<BR><BR><B><I>Roger <gagnonr001@hawaii.rr.com></I></B>=20
wrote:</DIV>
<BLOCKQUOTE=20
style=3D"PADDING-LEFT: 5px; MARGIN-LEFT: 5px; BORDER-LEFT: #1010ff 2px =
solid">Tomas<BR>Right=20
I am very happy with the $8,000 I was just about to sell when my=20
Gain<BR>when to 25% which it was but I got a overseas phone call. =
Was on the=20
line<BR>for an hour when I got back to my PC APPX was down $4 I =
couldn't=20
believe.<BR>When it go to just under$31 I got out..Well now I am =
looking for=20
another to<BR>buy.. I try to buy 2000 sh for those under 30 and =
1,500 or=20
1,000 for those<BR>above depending. Well I will keep my eyes open =
for=20
another<BR>Roger<BR>----- Original Message ----- <BR>From: "Tomas"=20
<TOMAS986@YAHOO.COM><BR>To: <CANSLIM@LISTS.XMISSION.COM><BR>Sent: =
Wednesday,=20
May 28, 2003 10:54 AM<BR>Subject: Re: [CANSLIM] APPX -- any idea =
what is=20
happening<BR><BR><BR>> BTW Roger, Congrats on the $8K gain. Half =
the=20
orginal<BR>> gain... but can't be too greedy :).<BR>><BR>>=20
tomas<BR>><BR>> --- Roger =
<GAGNONR001@HAWAII.RR.COM>wrote:<BR>>=20
> Pritish<BR>> > I don't know what happened but I got out =
at $31=20
made<BR>> > about $8,000 profit but<BR>> > was looking =
at a=20
$16,000 profit earlier in the day<BR>> > well atleast I =
made<BR>>=20
> something<BR>> > Roger<BR>> > ----- Original =
Message -----=20
<BR>> > From: "Pritish Shah" <PSHAH@LASON.COM><BR>> > =
To:=20
<CANSLIM@LISTS.XMISSION.COM><BR>> > Sent: Wednesday, May 28, =
2003 9:28=20
AM<BR>> > Subject: [CANSLIM] APPX -- any idea what is<BR>> =
>=20
happening<BR>> ><BR>> ><BR>> ><BR>> > Does =
anyone=20
have any idea on what is happening with<BR>> > this stock. It =
has=20
lost<BR>> > $5 in price in the last hour.<BR>> ><BR>> =
>=20
Regards,<BR>> > Pritish<BR>> ><BR>> ><BR>> > =
-<BR>> > -To subscribe/unsubscribe, email<BR>> >=20
"majordomo@xmission.com"<BR>> > -In the email body, write =
"subscribe=20
canslim" or<BR>> > -"unsubscribe canslim". Do not use quotes =
in=20
your<BR>> > email.<BR>> ><BR>> ><BR>> =
><BR>> >=20
-<BR>> > -To subscribe/unsubscribe, email<BR>> >=20
"majordomo@xmission.com"<BR>> > -In the email body, write =
"subscribe=20
canslim" or<BR>> > -"unsubscribe canslim". Do not use quotes =
in=20
your<BR>> email.<BR>><BR>><BR>>=20
__________________________________<BR>> Do you Yahoo!?<BR>> =
Yahoo!=20
Calendar - Free online calendar with sync to Outlook(TM).<BR>>=20
http://calendar.yahoo.com<BR>><BR>> -<BR>> -To=20
subscribe/unsubscribe, email "majordomo@xmission.com"<BR>> -In =
the email=20
body, write "subscribe canslim" or<BR>> -"unsubscribe canslim". =
Do not=20
use quotes in your email.<BR><BR><BR><BR>-<BR>-To =
subscribe/unsubscribe,=20
email "majordomo@xmission.com"<BR>-In the email body, write =
"subscribe=20
canslim" or<BR>-"unsubscribe canslim". Do not use quotes in your=20
email.</BLOCKQUOTE>
<P>
<HR SIZE=3D1>
Do you Yahoo!?<BR>Free <A=20
=
href=3D"http://us.rd.yahoo.com/mail_us/tag/*http://calendar.yahoo.com">on=
line=20
calendar</A> with sync to Outlook(TM).</BLOCKQUOTE></BODY></HTML>
- ------=_NextPart_000_003D_01C3254C.F1F95F60--
- -
- -To subscribe/unsubscribe, email "majordomo@xmission.com"
- -In the email body, write "subscribe canslim" or
- -"unsubscribe canslim". Do not use quotes in your email.
Next Article (by Author): Re: [CANSLIM] BO, too fast too much "Pritish Shah"
Previous Article (by Author): RE: [CANSLIM] APPX -- any idea what is happening "Katherine Malm"
Top of Thread: [CANSLIM] APPX -- any idea what is happening "Pritish Shah"
Articles sorted by: [Date]
[Author]
[Subject]